Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 3.51 ($0.04) and last traded at GBX 3.68 ($0.05), with a volume of 2319499 shares traded. The stock had previously closed at GBX 3.78 ($0.05).
Wall Street Analysts Forecast Growth
Separately, Shore Capital reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, January 2nd.
Read Our Latest Research Report on POLB
Poolbeg Pharma Stock Down 2.8 %
About Poolbeg Pharma
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Read More
- Five stocks we like better than Poolbeg Pharma
- What is diluted earnings per share (Diluted EPS)?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- What Are Treasury Bonds?
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Why is the Ex-Dividend Date Significant to Investors?
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
